Homepage
A leading Biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease.

Biomind Labs is a pharmaceutical developer making drugs treating patients with neurological disorders plus customised drug-release products.
biomindlabs.comCrawled Nov 13, 2026
A leading Biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease.
Biomind Labs uses cookies to personalize user experiences on its platform.
Biomind Labs’ Privacy Policy explains how the company protects user data and maintains confidentiality.
Biomind Labs outlines its Terms of Use to provide clear guidelines for users.
Biomind Labs advances its **5-MEO-DMT drug candidate BMND08** through the FDA approval process using a proprietary nano-formulation. The company successfully defends against patent observations, clearing a key regulatory hurdle. Biomind also grants stock options to employees as part of its growth strategy.
Biomind Labs highlights rising U.S. interest in psychedelic research and therapy. The company notes growing support for studying and developing psychedelic-based treatments. This reflects broader momentum in clinical and regulatory discussions around psychedelics.
Biomind Labs highlights the U.S. administration’s nomination of a Health Secretary with a background in supporting psychedelic-based mental health treatments. The policy shift signals potential progress for psychedelic therapies in addressing neurological disorders. The company, specializing in next-generation pharmaceuticals, sees this as a pivotal moment for the industry.
A biotech company initiates the first clinical trial of a sublingual drug formulation aimed at reducing anxiety and depression symptoms in Alzheimer’s patients. The trial marks a Phase 2a study, focusing on early-stage safety and efficacy assessments. The formulation is designed for sublingual administration, potentially offering an alternative treatment approach for neuropsychiatric symptoms in Alzheimer’s disease.
Biomind Labs has begun the first clinical trial investigating **5-MeO-DMT** (BMND08), a sublingual formulation, to treat **depression and anxiety in Alzheimer’s patients**. The Phase II study targets neurological symptoms by addressing underlying disease drivers. The company specializes in developing next-generation pharmaceuticals for neurological disorders.